| Literature DB >> 28358337 |
Chen Hu1, Shi-Wen Zhou2, Fang Chen3, Xin-Heng Zheng4, Hui-Fang Shen5, Bi-Run Lin6, Guang-Xiong Zhou7.
Abstract
An actinomycete strain (H12-15) isolated from a sea sediment in a mangrove district was identified as Streptomycesantibioticus on the basis of 16S rDNA gene sequence analysis as well as the investigation of its morphological, physiological, and biochemical characteristics. Two novel benzamido nonacyclic dilactones, namely neoantimycins A (1) and B (2), together with the known antimycins A1ab (3a,b), A2a (4), and A₉ (5), were isolated from the culture broth of this strain. Compounds 1 and 2 are the first natural modified ATNs with an unusual benzamide unit. The structures of these new compounds, including their absolute configuration, were established on the basis of HRMS, NMR spectroscopic data, and quantum chemical ECD calculations. Their cytotoxicities against human breast adenocarcinoma cell line MCF-7, the human glioblastoma cell line SF-268, and the human lung cancer cell line NCI-H460 were also tested. All compounds exhibited mild cytotoxic activity. However, Compounds 1 and 2 showed no activity against C. albicans at the test concentration of 1 mg/mL via paper disc diffusion, while the known antimycins showed obvious antifungal activity.Entities:
Keywords: ECD calculations; Streptomyces antibioticus; antifungal activity; cytotoxicity; neoantimycins A and B; secondary metabolite; strain identification
Mesh:
Substances:
Year: 2017 PMID: 28358337 PMCID: PMC6154602 DOI: 10.3390/molecules22040557
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of Compounds 1–5.
Figure 2Key 1H–1H COSY and HMBC correlations for Compounds 1 (A) and 2 (B).
Figure 3Key NOESY correlations of 1.
Figure 4Experimental ECD spectra of 1, 2, 4, and the calculated ECD spectra of (3R,4S,7R,8R,9S,2′′′S)-1 and (3R,4S,7R,8R,9S,2′′′R)-1.
Figure 5The chemical structure of 1.
1H- and 13C-NMR spectral data of new Compounds 1 and 2 (CDCl3, δ in ppm).
| No. | 1 | 2 | ||
|---|---|---|---|---|
| 2 | 170.8 | - | 170.8 | - |
| 3 | 54.2 | 5.34, t, 7.8 | 54.2 | 5.34, t, 7.8 |
| 4 | 71.5 | 5.75, p, 6.7 | 71.5 | 5.75, p, 6.8 |
| 6 | 173.2 | - | 173.2 | - |
| 7 | 50.3 | 2.50, m | 50.3 | 2.52, m |
| 8 | 75.6 | 5.09, t, 9.9 | 75.6 | 5.08, t, 9.9 |
| 9 | 74.6 | 4.99, m | 74.6 | 5.00, m |
| 10 | 18.0 | 1.28, d, 6.1 | 18.0 | 1.28, d, 6.5 |
| 11 | 15.2 | 1.32, d, 6.7 | 15.2 | 1.32, d, 6.7 |
| 1′ | 133.4 | - | 133.4 | - |
| 2′ | 127.3 | 7.82, d, 7.0 | 127.3 | 7.82, d, 7.4 |
| 3′ | 128.9 | 7.47, t, 7.6 | 128.9 | 7.47, t, 7.7 |
| 4′ | 132.3 | 7.55, t, 7.3 | 132.3 | 7.55, t, 7.4 |
| 5′ | 128.9 | 7.47, t, 7.6 | 128.9 | 7.47, t, 7.7 |
| 6′ | 127.3 | 7.82, d, 7.0 | 127.3 | 7.82, d, 7.4 |
| 7′ | 167.0 | - | 167.0 | - |
| 1″ | 28.6 | 1.67, m | 28.5 | 1.66, m |
| 1.25, m | 1.25, m | |||
| 2″ | 22.6 | 1.25, m | 22.6 | 1.25, m |
| 3″ | 27.1 | 1.25, m | 27.2 | 1.25, m |
| 4″ | 31.6 | 1.25, m | 31.6 | 1.25, m |
| 5″ | 29.1 | 1.25, m | 29.1 | 1.25, m |
| 6″ | 14.2 | 0.85, t, 6.6 | 14.2 | 0.86, t, 6.8 |
| 1′′′ | 175.4 | - | 175.7 | - |
| 2′′′ | 41.4 | 2.41, dt, 10.6, 5.3 | 34.3 | 2.61, t, 7.0 |
| 3′′′ | 26.6 | 1.75, m | 19.1 | 1.22, d, 2.5 |
| 1.49, m | ||||
| 4′′′ | 11.9 | 0.94, t, 7.4 | 19.1 | 1.21, d, 2.5 |
| 5′′′ | 16.9 | 1.18, d, 7.0 | ||
| 7′-NH | - | 6.86, d, 7.8 | - | 6.85, d, 7.9 |
a Measured at 300 MHz. b Measured at 75 MHz. c Measured at 600 MHz. d Measured at 150 MHz.
Cytotoxic activities of 1–5 on MCF-7, SF-268, and NCI-H460 cancer cells lines.
| Compounds | MCF-7 | SF-268 | NCI-H460 |
|---|---|---|---|
| >50 | 33.6 | >50 | |
| >50 | 41.6 | >50 | |
| 18.1 | <1.6 | 21.7 | |
| 36.4 | <1.6 | 43.7 | |
| 26.1 | <1.6 | 15.5 | |
| Positive control | 4.0 | 41.0 | 25.1 |
Concentration range: 1.6–100 μg/mL. IC50: half maximal inhibitory concentration.